Sygnis SA (WSE:SYG)
Poland · Delayed Price · Currency is PLN 1.600
+0.060 (3.90%)
At close: Feb 27, 2026
Sygnis Revenue
In the year 2025, Sygnis had annual revenue of 11.34M PLN with 15.66% growth. Sygnis had revenue of 5.03M in the quarter ending December 31, 2025, with 50.82% growth.
Revenue
11.34M
Revenue Growth
-39.01%
P/S Ratio
3.87
Revenue / Employee
629.73K
Employees
13
Market Cap
43.88M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.34M | 1.53M | 15.66% |
| Dec 31, 2024 | 9.80M | -10.23M | -51.08% |
| Dec 31, 2023 | 20.03M | -8.48M | -29.73% |
| Dec 31, 2022 | 28.51M | 25.11M | 739.70% |
| Dec 31, 2021 | 3.39M | 600.08K | 21.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NEUCA | 13.34B |
| Diagnostyka | 2.30B |
| Synektik Spólka Akcyjna | 706.45M |
| Voxel | 568.83M |
| BioMaxima | 59.11M |
| Read-Gene | 15.57M |
| Pharmena | 1.58M |
| Medicofarma Biotech | 281.45K |